O7B

(3~{a}~{S})-2-[(3~{S})-1-azabicyclo[2.2.2]octan-3-yl]-3~{a},4,5,6-tetrahydro-3~{H}-benzo[de]isoquinolin-1-one

Find entries where: O7B

is present as a standalone ligand in 2 entries

Find related ligands:

Chemical Component Summary
Name	(3~{a}~{S})-2-[(3~{S})-1-azabicyclo[2.2.2]octan-3-yl]-3~{a},4,5,6-tetrahydro-3~{H}-benzo[de]isoquinolin-1-one
Synonyms	Palonosetron; Aloxi
Identifiers	(3~{a}~{S})-2-[(3~{S})-1-azabicyclo[2.2.2]octan-3-yl]-3~{a},4,5,6-tetrahydro-3~{H}-benzo[de]isoquinolin-1-one
Formula	C₁₉ H₂₄ N₂ O
Molecular Weight	296.407
Type	NON-POLYMER
Isomeric SMILES	c1cc2c3c(c1)C(=O)N(C[C@H]3CCC2)[C@@H]4CN5CCC4CC5
InChI	InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1
InChIKey	CPZBLNMUGSZIPR-NVXWUHKLSA-N

Chemical Details
Formal Charge	0
Atom Count	46
Chiral Atom Count	2
Bond Count	50
Aromatic Bond Count	6

Drug Info: DrugBank

DrugBank ID	DB00377
Name	Palonosetron
Groups	approved investigational
Description	Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Synonyms	2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one Palonosetron hydrochloride Palonosetronum Palonosétron Palonosetron Palonosetrón (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one
Brand Names	Palonosetron Hydrochloride Aloxi Akynzeo Palonosetron hydrochloride Palonosetron Accord Palonosetron Hospira Palonosetron
Indication	For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
Categories	Alimentary Tract and Metabolism Antidepressive Agents Antiemetic Serotonin 5-HT3 Receptor Antagonists Antiemetics Antiemetics and Antinauseants Autonomic Agents Central Nervous System Agents Central Nervous System Depressants Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 CYP2D6 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates Drugs that are Mainly Renally Excreted Gastrointestinal Agents Heterocyclic Compounds, Fused-Ring Isoquinolines Neurotransmitter Agents Peripheral Nervous System Agents Quinuclidines Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome Serotonin 3 Receptor Antagonists Serotonin 5-HT3 Receptor Antagonists Serotonin Agents Serotonin Receptor Antagonists
ATC-Code	A04AA55 A04AA05
CAS number	135729-56-5

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
5-hydroxytryptamine receptor 3A	MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVR...	unknown	antagonist
Cytochrome P450 2D6	MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...	unknown	substrate
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682